Quest Diagnostics (DGX) has reported a substantial increase in its
dividend to $0.86, marking an annual growth for the
15th consecutive year. On the back of this news, the firm has revealed a billon-dollar boost in
share repurchase authorization. Mizuho has posited a positive future for DGX stock price, which recently reached a
52-week high. Despite facing challenges from a long-term earnings decline narrative, DGX has recorded a strong
9% net margin resurgence. With the company's
advanced diagnostics and AI efficiency strategies, the bio-tech firm is on the cusp of a valuation recalculation. DGX's pursuit of higher value oncology growth with its innovative
MRD blood test for Myeloma will potentially lead to the resumption of this growth trend. Quest's Q4 expectations have been surpassed, with the company announcing an increased
dividend, share repurchase, and a profit hike. The company is also set to initiate a
new collaboration with Epic that promises to revolutionize laboratory testing experiences. DGX has pledged to repurchase an additional
$1 billion in outstanding stock while delivering optimistic FY 2026 earnings guidance.
Quest Diagnostics DGX News Analytics from Tue, 22 Jul 2025 07:00:00 GMT to Sat, 14 Feb 2026 10:42:39 GMT -
Rating 9
- Innovation 7
- Information 8
- Rumor 6
